AZ13705339 hemihydrate|CAS |DC Chemicals

Cas No.:
Chemical Name:	AZ13705339 hemihydrate
SMILES:	N#CC1=CC=CC=C1CN(C2=NC(NC3=CC=C(N4CCN(C)CC4)C(S(=O)(CC)=O)=C3)=NC=C2F)C5=CC(CO)=CC=C5C.[1/2].O
Formula:	C₃₃H₃₆FN₇O₃S^.₁/₂H₂O
M.Wt:	638.77
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Cat. No.	Product name	Field of application
DC7059	PF-03758309	PF-03758309 is an orally bioavailable small-molecule inhibitor of p21-activated kinase 4 (PAK4) with potential antineoplastic activity.
DC9887	FRAX1036	FRAX1036 is a novel ATP-competitive small molecule inhibitor of group I p21-activated Kinases (PAKs).
DC11199	CZh226	CZh226 hydrochloride (CZh-226) is a potent, selective inhibitor of p21-activated kinase 4 (PAK4) with Ki of 9 nM, displays 346-fold selectivity over PAK-1.
DC72129	AZ13705339 hemihydrate	AZ13705339 hemihydrate is a highly potent and selective PAK1 inhibitor with IC50s of 0.33 nM and 59 nM for PAK1 and pPAK1, respectively. AZ13705339 hemihydrate has binding affinities to PAK1 and PAK2, with Kds of 0.28 nM and 0.32 nM, respectively. AZ13705339 hemihydrate can be used in the research of cancers.
DC70514	IPP-14	IPP-14 is a novel PAK1 inhibitor that selectively blocks the PAK1-PUMA binding and suppresses cell proliferation via PUMA-dependent manner; suppresses cancer cell viability and migration, induces p21 expression and induces M-phase arrest by inhibition of PAK1; also induces p21/WAF1/CIP1 (Cyclin-dependent kinase inhibitor 1A) expression by releasing from Bcl-2 and by inhibition of AKT-mediated p21 suppression.